Table 5.
Cardiovascular Events and Mortality Rates With SGLT-2 Inhibitors in Meta-Analyses of Randomized Controlled Trials (Phase 2 to 3 Trials Plus EMPA-REG OUTCOME)
Cardiovascular Events and Mortality Rates With SGLT-2 Inhibitors in Meta-Analyses of Randomized Controlled Trials (Phase 2 to 3 Trials Plus EMPA-REG OUTCOME)